Kintor Pharmaceutical Ltd. has announced the superior efficacy of its clinical observational study involving KX-826 combined with minoxidil for treating male adults with androgenetic alopecia (AGA) in China. This study, which received clearance from the National Medical Products Administration, aims to assess the efficacy and safety of the combination treatment compared to minoxidil monotherapy. Conducted at two clinical research centers in China, the study's primary endpoint is the change in target area non-vellus hair counts after 24 weeks, with secondary endpoints including hair growth assessments from both investigators and patients. This development represents a significant step in advancing the phase III clinical trial protocol, optimizing key factors such as dose selection and patient enrollment numbers. Shareholders and potential investors are advised to stay informed about these promising advancements.